Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 6 - Commitments and Contingencies (Details Textual)

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)									1 Months Ended		3 Months Ended	9 Months Ended	10 Months Ended	12 Months Ended
	Feb. 28, 2017	Oct. 31, 2016	Oct. 13, 2016	Jul. 31, 2016	May 27, 2016	Jun. 16, 2015	Jun. 03, 2015	Oct. 31, 2014	May 31, 2016	Mar. 31, 2016	Mar. 31, 2016	Sep. 30, 2016	Oct. 31, 2016	Dec. 31, 2015
Former Owners of RedPath [Member] \| Subsequent Event [Member]
Loss Contingency Accrual, Payments													$ 170,000
Former Owners of RedPath [Member]
Business Combination, Indemnification Assets, Amount as of Acquisition Date								$ 2,500,000
DOJ [Member] \| Subsequent Event [Member]
Loss Contingency Accrual, Payments		$ 85,000
DOJ [Member] \| Scenario, Forecast [Member]
Loss Contingency Accrual, Payments	$ 80,000
DOJ [Member]
Loss Contingency, Renegotiated, Amount									$ 250,000
Loss Contingency Accrual, Payments				$ 85,000
Subsequent Event [Member] \| Companys Counter-claim Against Prolias [Member]
Litigation Settlement, Amount			$ 500,000
Loss Contingency, Damages Sought, Value			$ (621,236.16)
Loss Contingency, Interest on Settlement			10.00%
Loss Contingency Damages Sought, Value, Attorney Fees			$ 390,769.04
Other Accrued Expenses [Member]
Regulatory Liabilities												$ 700,000
Other Noncurrent Liabilities [Member]
Regulatory Liabilities												1,000,000
Companys Counter-claim Against Prolias [Member]
Loss Contingency, Damages Sought, Value							$ 500,000
Notes Issued							$ 1,000,000
Swann vs. Akorn, Inc, and Interpace Diagnostics Group, Inc. [Member]
Loss Contingency, Damages Sought, Value					$ 300,000
Continuing Operations [Member]
Severance Costs											$ 500,000	2,300,000
Discontinued Operations [Member]
Severance Costs												800,000
Letters of Credit Outstanding, Amount												$ 300,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares						500,000		500,000		500,000
Common Stock, Par or Stated Value Per Share								$ 0.01				$ 0.01		$ 0.01
Adjustments to Additional Paid in Capital, Other						$ (6,100,000)				$ (6,800,000)
Stock Issued During Period, Value, Treasury Stock Reissued						$ 6,100,000				$ 6,800,000
Litigation Settlement, Amount								$ 3,000,000
Regulatory Liabilities												$ 1,700,000
Severance Costs											$ 1,100,000	$ 3,100,000		$ 3,700,000